Formula I Antibacterial Compounds Overcoming MDR Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of Multidrug Resistant (MDR) bacterial pathogens, such as Pseudomonas aeruginosa, poses a significant challenge due to their ability to develop resistance mechanisms against conventional antibiotics, including efflux pumps that reduce the efficacy of antibacterial agents, necessitating the need for novel antibiotics with new mechanisms of action and improved properties.
Innovation Solution
Compounds of formula I, when used alone or in combination with a bacterial efflux pump inhibitor, exhibit antibacterial activity, providing a method for treating or preventing bacterial infections by targeting MDR pathogens effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then treatment effectiveness is maintained against susceptible bacteria, but resistance develops leading to treatment failure against MDR pathogens
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of antibiotics to create novel compounds with altered properties. The general formula encompasses multiple compounds with varying substituents (R1-R6) that modify pharmacokinetic and pharmacodynamic parameters, enabling these compounds to overcome bacterial resistance mechanisms while maintaining therapeutic effectiveness against MDR pathogens.
Solution Approach 2:
The patent utilizes composite materials by combining antibiotic compounds with efflux pump inhibitors in formulations. This composite approach addresses resistance by simultaneously delivering two functional components: the antibiotic to kill bacteria and the efflux pump inhibitor to prevent drug expulsion, creating a synergistic effect that overcomes MDR mechanisms.
2Reliability
If efflux pumps are active in bacteria, then drug concentration at target site is reduced allowing bacterial survival, but this resistance mechanism can be overcome by combining with efflux pump inhibitors
Solution Approach 1:
The patent applies the intermediary principle by introducing efflux pump inhibitors as mediator compounds that interfere with the bacterial efflux pump system. These inhibitors act as intermediaries that block the pump's ability to expel antibiotics, thereby increasing intracellular drug concentration and restoring antibiotic efficacy against MDR bacteria.
Solution Approach 2:
The patent converts the harmful efflux pump mechanism into a benefit by using the same pump system's vulnerability against it. The efflux pump inhibitors exploit the pump's structure and function to disable it, turning the bacteria's resistance mechanism into a target for therapeutic intervention and restoring drug susceptibility.
3Adaptability or versatility
If new antibiotics with novel mechanisms of action are developed, then resistance mechanisms are circumvented, but formulation characteristics and toxicity need improvement
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic approach into distinct functional components represented by different substituent patterns in the general formula. Each compound variant with specific R1-R6 substitutions represents a segmented approach to optimizing different properties (solubility, stability, activity) separately, allowing systematic improvement of formulation characteristics while maintaining the core novel mechanism of MreB inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit bacterial infections by overcoming resistance mechanisms, offering a novel approach to combatting MDR pathogens and improving treatment outcomes.
Implementation Method 1
Studies with various MreB homnologs have established that this protein forms dynamic, actin-like helical filaments in an ATP- or GTP-dependent fashion.
Implementation Method 2
Pseudomonas aeruginosa expresses numerous efflux pumps including MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprA(OprM) which actively efflux various antibacterial agents.
Data Source
AI summary
Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in combination with a bacterial efflux pump inhibitor.